PsyBio Therapeutics Corp.
PSYBF
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 100.00% | -- | |||
| Gross Profit | -100.00% | -- | |||
| SG&A Expenses | -81.19% | -1.34% | |||
| Depreciation & Amortization | -- | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -79.13% | -16.53% | |||
| Operating Income | 79.13% | 16.53% | |||
| Income Before Tax | 77.57% | 13.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 77.57% | 13.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.57% | 13.82% | |||
| EBIT | 79.13% | 16.53% | |||
| EBITDA | 80.68% | 17.26% | |||
| EPS Basic | 77.78% | 25.88% | |||
| Normalized Basic EPS | 80.00% | 23.08% | |||
| EPS Diluted | 77.78% | 25.88% | |||
| Normalized Diluted EPS | 80.00% | 23.08% | |||
| Average Basic Shares Outstanding | 0.00% | 15.13% | |||
| Average Diluted Shares Outstanding | 0.00% | 15.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||